Quantum Computing Inc. Posts $9.5M Q3 Revenue as Dirac-3S Nears Shipments

iconCryptoBriefing
Share
AI summary iconSummary
Quantum Computing Inc. (QUBT) reported $9.5 million in Q3 2026 revenue, up 71% from Q2. The firm is set to ship its Dirac-3S system in Q4 and holds $1.3 billion in cash. Altcoins to watch may include QUBT as the company moves closer to product delivery. Despite the revenue jump, QUBT posted a $15.15 million net loss due to rising costs. Market sentiment, as reflected in the fear and greed index, remains mixed ahead of key crypto earnings.

Quantum Computing Inc. (QUBT) just had the kind of quarter that makes a research lab look like an actual business. The company reported third-quarter 2026 revenue of $9.5 million, up from $5.55 million in the prior quarter.

A year earlier, the same quarter brought in $384,000.

The photonics developer, which builds hardware that uses particles of light to process information, is moving from research toward commercial sales.

Where the money came from

The sequential jump works out to a 71% increase over the second quarter. For context, revenue for the entire first half of 2026 was approximately $9.2 million.

So the third quarter on its own outearned the previous six months combined.

The engine behind it is a string of acquisitions in photonics and semiconductors. Those deals brought in Luminar Semiconductors, NuCrypt, and NHanced, and with them a set of paying customers.

Those customers sit mostly in aerospace, government, and industrial markets.

QUBT posted a net loss of $15.15 million for the quarter, driven largely by rising operating expenses tied to integrating acquisitions, hiring, and commercialization work.

Dirac-3S and the balance sheet behind it

The product headline is the Dirac-3S, the company’s optimization system. It can scale to 9,980 variables, and QUBT expects first customer shipments in the fourth quarter of 2026.

Optimization problems are the “find the best option among millions” puzzles: the most efficient delivery routes, the best mix of assets in a portfolio, the smartest allocation of limited resources. QUBT positions the Dirac platform for logistics, finance, and defense use cases.

The company’s approach is what it calls room-temperature entropy quantum optimization. The practical selling point is the “room-temperature” part, since a system that does not need extreme cooling is easier to install outside a specialized lab.

QUBT holds approximately $1.3 billion in cash, cash equivalents, and investments.

Some of that cash is already earmarked. QUBT plans to spend $70 million to $80 million expanding its NHanced Fab 2 manufacturing facility, with the work targeted for completion by March 2027.

Backlog, partners, and the road from lab to market

QUBT ended the quarter with a contract backlog of $39.1 million, and most of those contracts are anticipated to convert into revenue over the next 12 months.

The company also signed new deals during the quarter. It entered a commercial partnership with INmune Bio and a framework agreement with Hamad Bin Khalifa University.

What this means for QUBT investors

Much of the growth is acquired, which means it reflects deal-making as much as demand for QUBT’s own quantum optimization technology.

The fourth-quarter Dirac-3S shipments are the near-term test.

Investors should watch a few items closely over the coming quarters. Key signals include how quickly the $39.1 million backlog converts, whether the NHanced Fab 2 project stays on budget and on schedule for March 2027, and how many Dirac-3S units actually ship.

Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information. Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.